Multimodal Retinal Imaging for the Detection of Early Alzheimer’s Disease: Combining Biochemical, Structural, and Vascular Biomarkers
Authors:
- Michiel GhesquiereMichiel Ghesquiere
- Eirini ChristinakiEirini Christinaki
- Sophie LemmensSLSophie Lemmens
- Jan Van EijgenJEJan Van Eijgen
- Lennert BeeckmansLBLennert Beeckmans
- Achilleas GhinisAGAchilleas Ghinis
- Thomas JacobsTJThomas Jacobs
- Karel Van KeerKKKarel Van Keer
- Zahi WehbiZWZahi Wehbi
- Lies De GroefLGLies De Groef
- Yasmin Dahdouh-GuebasYDYasmin Dahdouh-Guebas
- Wouter CharleWCWouter Charle
Open Access
- 8 September 2026
- journal article
- research article
- Published by MDPI AG in Bioengineering
- Vol. 13 (9) , 1041
Abstract
Alzheimer’s disease (AD) pathology is increasingly recognized to manifest in the retina, offering a non-invasive window for early biomarker discovery. This proof-of-concept study investigated whether multimodal retinal imaging—hyperspectral imaging (HSI), optical coherence tomography (OCT), and color fundus photography (CFP)—can differentiate individuals with and without cerebral amyloid-beta (Aβ) pathology in 40 participants with PET-confirmed Aβ status (17 Aβ+, cognitively normal or with mild cognitive impairment; 23 Aβ− cognitively normal controls). HSI-derived gray-level co-occurrence matrix (GLCM) texture, OCT-derived ganglion cell–inner plexiform layer (GC-IPL) thickness, and CFP-derived vascular biomarkers (VBMs) were extracted, and logistic regression with leave-one-out cross-validation assessed classification performance per modality, alone and combined; the cohort was supplemented with AD dementia patients for an exploratory cross-sectional comparison across disease-stage groups. HSI showed nominally lower GLCM correlation at 466 nm in Aβ+ participants, most pronounced in the inferior macula (AUC = 0.72). GC-IPL thickness showed a similar inferior-predominant regional pattern. Combining HSI and GC-IPL features yielded the best performance (AUC = 0.84; sensitivity = 0.82; specificity = 0.78), although this improvement over the unimodal models did not reach statistical significance, whereas vascular biomarkers contributed minimally. In an exploratory cross-sectional comparison across AD stage groups drawn from two cohorts, HSI features showed a non-monotonic pattern, decreasing in early Aβ+ stages and rising again in dementia. These findings provide preliminary evidence of complementary information between HSI and OCT for detecting retinal biomarkers of early-stage AD, supporting multimodal retinal imaging as a scalable screening approach warranting validation in larger, longitudinal cohorts.Keywords
All Related Versions
Funding Information
- Fonds Wetenschappelijk Onderzoek (12ZZM23N)
- Fonds Wetenschappelijk Onderzoek (1SHC824N)
- Fonds Wetenschappelijk Onderzoek (G0C0319N)
- Fonds Wetenschappelijk Onderzoek (1292326N)
- Stichting Alzheimer Onderzoek (2020/0032)
- Stichting Alzheimer Onderzoek (2021/0036)
- EU Joint Programme–Neurodegenerative Disease Research (FWO-ERANET S007721N)
- KU Leuven (C24/18/095)
- KU Leuven (C24-17-063)
- Sequoia Fund for Research on Ageing and Mental Health
- Fonds Wetenschappelijk Onderzoek (12Y1623N)
- Fonds Wetenschappelijk Onderzoek (G093218N)
This publication has 89 references indexed in Scilit:
- Integrated analysis of in vivo retinal perivascular amyloid imaging and cognitionAlzheimer's & Dementia, 2025
- Retinal vascular biomarkers in mild cognitive impairment and Alzheimer's disease: a comprehensive review and meta‐analysisAlzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 2025
- Alzheimer's disease drug development pipeline: 2025Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2025
- Utilizing deep learning to predict Alzheimer's disease and mild cognitive impairment with optical coherence tomographyAlzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 2025
- Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association WorkgroupAlzheimer's & Dementia, 2024
- Retinal microvasculature and incident dementia over 10 years: The Three‐City‐Alienor cohortAlzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 2023
- Primary retinal tauopathy: A tauopathy with a distinct molecular patternAlzheimer's & Dementia, 2023
- Longitudinal changes in Alzheimer's‐related plasma biomarkers and brain amyloidAlzheimer's & Dementia, 2023
- Global estimates on the number of persons across the Alzheimer's disease continuumAlzheimer's & Dementia, 2022
- Association of Retinal Changes With Alzheimer Disease Neuroimaging Biomarkers in Cognitively Normal IndividualsJAMA Ophthalmology, 2021